Xyrem

ApprovedSmall molecule

Jazz Pharmaceuticals

Xyrem is one of 133 small molecule programs targeting Obstructive Sleep Apnea. It is currently in Approved.

Indications

Total Trials

Active Trials

132

Competitors

Pipeline

Status by Indication[3][1]

Indication

Obstructive Sleep ApneaActive, not recruiting

InsomniaActive, not recruiting

NarcolepsyActive, not recruiting

FibromyalgiaActive, not recruiting

Obstructive Sleep ApneaApproved

Active, not recruiting

InsomniaPhase 2

Active, not recruiting

NarcolepsyPhase 3

Active, not recruiting

FibromyalgiaPhase 3

Active, not recruiting

Competition

Competitive Landscape

153 competitors in Insomnia

#DrugCompanyPhaseTrials

Elavil

AstraZeneca

Phase 3

1 2

Neurontin

VViatris Specialty LLC

Phase 3

7 3

Hetlioz

VVanda Pharmaceuticals

Phase 3

2 4

Xyrem

Jazz Pharmaceuticals

Approved

1 5

Gaboxadol

Lundbeck

Phase 3

8 6

Eplivanserin

Sanofi

Phase 3

6 7

Volinanserin

Sanofi

Phase 3

2 8

Prosom

AAbbott

Phase 3

4 9

Org 50081

Merck & Co.

Phase 3

1 10

Zolpidem MR

Astellas

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Narcolepsy4 trials

A Multicenter Study of the Efficacy and Safety of Xyrem With an Open- Label Pharmacokinetic Evaluation and Safety Extension in Pediatric Subjects With Narcolepsy With Cataplexy

Completed· Jazz Pharmaceuticals logo

Jazz Pharmaceuticals·Phase 3·NCT02221869·106 enrolled

Trial of Xyrem® (Sodium Oxybate) for the Treatment of Narcolepsy

Completed· Jazz Pharmaceuticals logo

Jazz Pharmaceuticals·Phase 3·NCT00132873·59 enrolled

Trial Comparing Effects of Xyrem Taken Orally and Modafinil With Placebo in Treating Daytime Sleepiness in Narcolepsy

Completed· Jazz Pharmaceuticals logo

Jazz Pharmaceuticals·Phase 3·NCT00066170·231 enrolled

Show 1 more trial

Xyrem and Brain Dopamine in Narcolepsy

Completed·CCentre for Addiction and Mental Health·Phase 4·NCT02637076·17 enrolled

Fibromyalgia4 trials

A Safety and Efficacy Study of Xyrem® in Subjects With Fibromyalgia

Completed· Jazz Pharmaceuticals logo

Jazz Pharmaceuticals·Phase 3·NCT00371137·548 enrolled

Trial Comparing the Effects of Xyrem (Sodium Oxybate) With Placebo for the Treatment of Fibromyalgia

Completed· Jazz Pharmaceuticals logo

Jazz Pharmaceuticals·Phase 2·NCT00087555·195 enrolled

Safety and Efficacy Study of Xyrem® (Sodium Oxybate) in Subjects With Fibromyalgia.

Completed· Jazz Pharmaceuticals logo

Jazz Pharmaceuticals·Phase 3·NCT00423605·560 enrolled

Show 1 more trial

A Safety and Efficacy Study of Xyrem® (Sodium Oxybate) to Treat Fibromyalgia.

Completed· Jazz Pharmaceuticals logo

Jazz Pharmaceuticals·Phase 3·NCT00423813·573 enrolled

Obstructive Sleep Apnea1 trial

Trial of Effects of Oral Xyrem and Zolpidem on Sleep-Disordered Breathing in Obstructive Sleep Apnea Patients

Completed· Jazz Pharmaceuticals logo

Jazz Pharmaceuticals·Phase 4·NCT00086281·60 enrolled

Insomnia1 trial

Xyrem for Treatment Refractory Insomnia Due to PTSD

Withdrawn·SState University of New York - Upstate Medical University·Phase 2·NCT00330291

Sources

References

[1]
ClinicalTrials.gov — 10 trial records for Xyrem. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Xyrem compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Xyrem. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Jazz Pharmaceuticals company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Jazz Pharmaceuticals

Xyrem

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Narcolepsy4 trials

Fibromyalgia4 trials

Obstructive Sleep Apnea1 trial

Insomnia1 trial

References

Drug Info

Quick Facts

Related News